rethinkPeptides Search
Menu
Study breakdown

Bariatric Surgery vs GLP-1 Drugs Over 3 Years in Medicare and Medicaid Patients

evidence
The takeaway

Three-year analysis of Medicare and Medicaid patients compares bariatric surgery to GLP-1 receptor agonists for diabetes management and weight loss outcomes.

3-year real-world comparison

Surgery vs GLP-1 drugs in Medicare and Medicaid diabetes patients

What the researchers found

Three-year comparison of bariatric surgery versus GLP-1 RAs in Medicare and Medicaid patients with diabetes provides real-world effectiveness data in a publicly insured population.

Why it matters

Medicare and Medicaid patients face unique access barriers and disease burdens. Understanding treatment effectiveness in this population guides coverage decisions and equity.

How the study worked

Retrospective 3-year analysis of Medicare and Medicaid claims data comparing outcomes between bariatric surgery and GLP-1 RA treatment in patients with diabetes.

What this study cannot tell us

Retrospective claims analysis — cannot account for all confounders. Selection bias between surgery and medication patients is significant.

How to read the evidence

Retrospective claims analysis — provides real-world effectiveness data but limited by observational design and selection bias.

When this study was published

Published in 2026; reflects current treatment patterns in public insurance.

The bigger picture

As GLP-1 drug coverage expands in public insurance, comparing their real-world value to established bariatric surgery informs healthcare policy and resource allocation.

Questions still open

  • Which treatment is more cost-effective over 3 years in publicly insured patients?
  • Do outcomes differ between Medicare and Medicaid subpopulations?

Common questions

Is surgery or medication better for weight loss?
Both bariatric surgery and GLP-1 drugs are effective, but they work differently. Surgery typically produces more weight loss but is irreversible; GLP-1 drugs are less invasive but require ongoing use. This study compares their 3-year outcomes in real-world practice.
Does Medicare cover GLP-1 drugs for weight loss?
Medicare coverage for GLP-1 drugs has been evolving. This study provides data on real-world outcomes that can inform coverage decisions for these increasingly prescribed medications.

Read the original research

Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis.

Surgical endoscopy, 40(1), 671-678

Citation

Brown, Avery; Patel, Suhani S; Li, Elizabeth; Vu, Alexander Hien; Somoza, Eduardo; Chen, Jialin; Zhang, Donglan; Massie, Allan B; Orandi, Babak J; Segev, Dorry; Parikh, Manish; Chhabra, Karan. (2026). Bariatric surgery vs. GLP-1 receptor agonists among primarily medicare and medicaid patients with diabetes: a 3-year analysis.. Surgical endoscopy, 40(1), 671-678. https://doi.org/10.1007/s00464-025-12403-y